RankAlpha logo
Back to Rankings

DMRA

Damora TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The bull case is that Damora now has a well-funded post-merger platform, stated cash of $257.6 million at December 31, 2025, runway said to extend into Phase 3 development of DMR-001, and a clear mid-2026 IND/CTA target for the lead mutCALR program, leaving room for a sharp rerating if execution stays on schedule [#10-K-2026-03-19].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +2.2.
What can break
Cash runway could shorten if development pace or operating spend rises faster than planned
Momentum
81
Value
42
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $38.00 · Bear $14.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $46.75
Why
Momentum81 · Δ7d +2.2
Value42 · Δ7d +0.1
Sentiment56 · Δ7d +5.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
81
34% active weight
Current posture
7d trendSoftening
Δ7d
+2.2
Δ21d
-11.2
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
56
33% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
+5.8
Why this grade

Composite grade B. Momentum 81.0 / Value 41.9 / Sentiment 55.7

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.41B
Beta
1.43
Shares Out
1.59M
P/E (TTM) · Derived
-47.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-95.86
Rev YoY
-
EPS YoY
+30.4%
Gross Margin
-
Op Margin
-
Net Debt
-$14.18M
Current Ratio
3.73
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology